Detalles de la búsqueda
1.
A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer.
BMC Cancer
; 23(1): 708, 2023 Jul 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-37507657
2.
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
Invest New Drugs
; 38(5): 1570-1579, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32140889
3.
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer.
Br J Cancer
; 119(10): 1208-1214, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30318515
4.
Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.
Int J Mol Sci
; 18(5)2017 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28481241
5.
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-ß receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.
Invest New Drugs
; 33(2): 357-70, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25529192
6.
Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-ßRI inhibitor galunisertib.
PLoS One
; 16(6): e0253671, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34138968
7.
Safety and activity of the TGFß receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.
J Immunother Cancer
; 9(3)2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33688022
8.
First-In-Human Phase I Study of a Next-Generation, Oral, TGFß Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer.
Clin Cancer Res
; 27(24): 6666-6676, 2021 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34548321
9.
Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-ßRI inhibitor galunisertib.
PLoS One
; 15(3): e0222259, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32210440
10.
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER.
Front Oncol
; 10: 578756, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33194700
11.
TGFß receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer.
Cancer Chemother Pharmacol
; 83(5): 975-991, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30887178
12.
Pooling samples within microarray studies: a comparative analysis of rat liver transcription response to prototypical toxicants.
Physiol Genomics
; 22(3): 346-55, 2005 Aug 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-15914576
13.
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.
Drug Des Devel Ther
; 9: 4479-99, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-26309397
14.
First-in-human dose study of the novel transforming growth factor-ß receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma.
Clin Cancer Res
; 21(3): 553-60, 2015 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25424852
15.
Transcriptome signature of resistance exercise adaptations: mixed muscle and fiber type specific profiles in young and old adults.
J Appl Physiol (1985)
; 112(10): 1625-36, 2012 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-22302958
16.
Assessment of diet-induced obese rats as an obesity model by comparative functional genomics.
Obesity (Silver Spring)
; 16(4): 811-8, 2008 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-18239588
Resultados
1 -
16
de 16
1
Próxima >
>>